Roivant Sciences Ltd. (NASDAQ: ROIV) is a top low-cost stock to buy with Citigroup raising its price target to $35 following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. H.C. Wainwright also raised the price target to $33, while Bank of America increased it to $26, all citing strong results. The drug’s growth potential is driving optimism for future revenue projections.

Roivant Sciences (ROIV) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies. While ROIV shows promise as an investment, other AI stocks may offer greater upside potential with less downside risk, especially in light of current economic trends.

Investors looking for potential AI stock opportunities can explore a free report on the best short-term AI stock that stands to benefit from Trump-era tariffs and the onshoring trend. Consider other stocks that are projected to double in three years or hidden AI stocks to diversify your investment portfolio. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data